InDevR Raises $7 million in Series A Financing with Adjuvant Capital

Boulder, CO, 10 September 2019 – InDevR, Inc., a biotechnology [...]

InDevR Raises $7 million in Series A Financing with Adjuvant Capitalrodriguez2024-05-23T07:19:16-06:00

[Press Release] New VaxArray Potency Test Kit for Pandemic Flu Vaccines

[Press Release] InDevR launches a new product that could shave weeks [...]

[Press Release] New VaxArray Potency Test Kit for Pandemic Flu VaccinesInDevR Admin2024-05-23T07:55:15-06:00

InDevR licenses Mount Sinai influenza antibodies

InDevR licenses Mount Sinai influenza antibodies for VaxArray neuraminidase potency [...]

InDevR licenses Mount Sinai influenza antibodiesInDevR Admin2024-05-23T07:57:24-06:00

InDevR Receives NIH Support for VaxArray® Pandemic

InDevR Receives NIH Support for VaxArray® Pandemic Influenza Vaccine Potency [...]

InDevR Receives NIH Support for VaxArray® PandemicInDevR Admin2024-05-23T07:56:47-06:00

InDevR Cypher One™ Collaborative Study With FDA Published

InDevR Cypher One™ Collaborative Study With FDA Published InDevR, FDA [...]

InDevR Cypher One™ Collaborative Study With FDA PublishedInDevR Admin2021-01-05T11:34:41-07:00